Information relative au nombre total de droits de vote et d’actions composant le capital social au 22 mai 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.